RECRUITING

WE-TRUST (Workflow Optimization to Reduce Time to Endovascular Reperfusion for Ultra-fast Stroke Treatment)

Talk to us

Conditions

Stroke, Acute

Quick Navigation

Study Overview

This clinical trial focuses on testing the efficacy of different digital interventions to promote re-engagement in cancer-related long-term follow-up care for adolescent and young adult (AYA) survivors of childhood cancer.

Description

The WE-TRUST study is a multi-center randomized clinical trial to assess the impact of a Direct to Angio Suite (DTAS) workflow on stroke patient outcomes.

Official Title

WE-TRUST (Workflow Optimization to Reduce Time to Endovascular Reperfusion for Ultra-fast Stroke Treatment)

Quick Facts

Study Start:2021-06-23
Study Completion:2025-12-01
Study Type:Not specified
Phase:Not Applicable
Enrollment:Not specified
Status:RECRUITING

Study ID

NCT04701684

Participation Criteria

Researchers look for people who fit a certain description, called eligibility criteria. Some examples of these criteria are a person's general health condition or prior treatments.

Ages Eligible for Study:18 Years
Sexes Eligible for Study:ALL
Accepts Healthy Volunteers:No
Standard Ages:ADULT, OLDER_ADULT
Inclusion CriteriaExclusion Criteria
  1. * Subject is 18 years of age or older, or of legal age to give informed consent per state or national law.
  2. * Baseline NIHSS score obtained prior to randomization must be equal or higher than 10 points.
  3. * Subjects with no significant pre-stroke functional disability (modified Rankin scale 0 - 2).
  4. * Subjects suspected of acute ischemic stroke with an estimated arrival time at a stroke center (clinical investigational site participating in this study) \< 6 hours from symptom onset. Symptom onset is defined as point in time the patient was last known well (at baseline).
  5. * Informed consent obtained from patient or his or her legally designated representative (if locally required).
  6. * Angiography suite immediately available.
  7. * Endovascular treatment team immediately available (Neurologist, Neurointerventionist, Anesthesiologist, Nursing, Technicians as per local standard practice)
  1. Pregnancy or breastfeeding
  2. Severe psychiatric disorders
  3. Active substance abuse
  4. Unstable medical conditions
  5. Inability to comply with study requirements

Contacts and Locations

Study Contact

Gerrits
CONTACT
+31 6 55 48 29 31
carin.gerrits@philips.com
Eshuis
CONTACT
+31 6 28 73 92 80
peter.g.eshuis@philips.com

Principal Investigator

Raul G Nogueira
PRINCIPAL_INVESTIGATOR
UPMC Stroke Institute, Pittsburgh
Marc Ribo
PRINCIPAL_INVESTIGATOR
Vall d'Hebron University Hospital, Barcelona

Study Locations (Sites)

Baptist Medical Center
Jacksonville, Florida, 32207
United States
Grady Memorial Hospital/Emory University
Atlanta, Georgia, 30303
United States
Montefiore Medical Center
The Bronx, New York, 10467
United States

Collaborators and Investigators

Sponsor: Philips Clinical & Medical Affairs Global

  • Raul G Nogueira, PRINCIPAL_INVESTIGATOR, UPMC Stroke Institute, Pittsburgh
  • Marc Ribo, PRINCIPAL_INVESTIGATOR, Vall d'Hebron University Hospital, Barcelona

Study Record Dates

These dates track the progress of study record and summary results submissions to ClinicalTrials.gov. Study records and reported results are reviewed by the National Library of Medicine (NLM) to make sure they meet specific quality control standards before being posted on the public website.

Study Registration Dates

Study Start Date2021-06-23
Study Completion Date2025-12-01

Study Record Updates

Study Start Date2021-06-23
Study Completion Date2025-12-01

Terms related to this study

Additional Relevant MeSH Terms

  • Stroke, Acute